Study of Injectable, Oral, and Vaginal Ring HIV Prevention Choices for Adolescents and Young Adults in Cape Town
Led by Desmond Tutu HIV Foundation · Updated on 2025-02-04
1800
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to understand how adolescents and young people in Cape Town, South Africa use different HIV pre-exposure prophylaxis PrEP products over an 18-month period. It focuses on both clinical and practical aspects, such as how long participants continuously use PrEP without stopping or switching products, and what helps or hinders their decision to start and keep using PrEP. The study includes HIV-negative adolescent girls, young women, gender and sexually diverse youth aged 15-29, and their sexual partners of any age.
Participants can choose from three PrEP options a daily oral tablet containing Tenofovir, a vaginal ring with Dapivirine that protects for up to one month, or an intramuscular injection of Cabotegravir lasting up to two months. They may stick with one product, switch between them, or pause and restart use at any time. The study takes place at two sites a mobile clinic that moves across the area and a fixed government healthcare clinic. Trained nurses provide PrEP and counseling designed with input from youth.
Those who join will be followed for at least seven months to assess short-term use and up to 18 months for longer-term use. Researchers will collect information on product use, safety, tolerability, acceptability, and HIV testing practices. Participants choices and experiences with PrEP will be monitored through regular visits, with flexibility to access refills at either clinic. The study aims to provide insights into real-world PrEP use and factors influencing adherence and continuation.
CONDITIONS
Brief Title
PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Older than 15 years (specific age criteria for some groups)
Currently living in the study area
Able to provide written informed consent and willing to receive injectable PrEP
You will not qualify if you...
Confirmed HIV-positive test or signs of acute HIV infection
Medical conditions or medications that contraindicate chosen PrEP product
Allergy to any study product
Do not spend enough time in the study area for residence, school, or work
Any medical, social, or other condition that may interfere with study conduct or safety
Currently enrolled in another HIV prevention trial that interferes with this study
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 7 months for short-term persistence; up to 18 months for long-term persistence
Participants choose and initiate one of three HIV prevention products: injectable Cabotegravir, oral Tenofovir tablets, or vaginal Dapivirine ring. Participants may continue, switch, stop, or restart their chosen product throughout the treatment period.
Regular visits to receive and manage chosen PrEP product over 7 to 18 months
Long-term Monitoring
Duration - Up to 18 months after treatment initiation
Participants are followed to assess the long-term persistence, safety, tolerability, and acceptability of their chosen PrEP product, with ongoing HIV testing and support.
Follow-up visits as part of ongoing monitoring up to 18 months
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Improving HIV Testing in European Hospitals by Introducing Dedicated HIV Teams A Multicenter Study Across Ten Countries
Improving Sexual and Reproductive Health, Nutrition, and Psychosocial Well-being of Female University Students in Ethiopia Through Mobile Technology
Study of Cardiovascular Risk in Children and Young Adults With Chronic Health Conditions
Evaluating Codivir with Standard Antiretroviral Therapy for Treatment-Naive Adults with HIV Infection
Randomized Trial of Colchicine to Reduce Coronary Artery Inflammation in People 50 and Older Living With HIV and High Cardiovascular Risk
Donation of Blood and Tissue Samples for Research on HIVAIDS-Related Cancers in Adults
Retrospective Study on Dental Care Needs for Adults Living With HIV in Pays de la Loire Using COREVIH Data
Comparison of DarunavirCobicistat Plus Lamivudine Versus DarunavirCobicistat Plus Tenofovir AlafenamideEmtricitabine
for Virologically Suppressed Adult Men With HIV
Evaluating Effectiveness and Safety at 24 and 48 Weeks
Comparing DarunavirCobicistat Plus Lamivudine to DarunavirCobicistat Plus TenofovirEmtricitabine
for Men with Controlled HIV-1 Infection in Mexico 48-Week Safety and Effectiveness Study
Testing a Digital PrEP Toolkit to Help Cisgender Women in Alabama and Mississippi Learn About and Start HIV Prevention Medication
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
PrEPared to choose: the protocol for an implementation study of the delivery of cabotegravir long-acting injectable pre-exposure prophylaxis (PrEP) as an HIV prevention product option within a real world PrEP choice context in cape town.